Industry News: Volume 10, Issue 22

INDUSTRY NEWS

Johnson & Johnson to End Talc-Based Baby Powder Sales in North America

By Tiffany Hsu and Roni Caryn Rabin

nytimes.com – Johnson & Johnson is discontinuing North American sales of its talc-based baby powder, a product that once defined the company’s wholesome image and that it has defended for decades even as it faced thousands of lawsuits filed by patients who say it caused cancer.

The decision to wind down sales of the product is a huge concession for Johnson & Johnson, which has for more than a century promoted the powder as pure and gentle enough for babies.

To view the original article in its entirety, click here.

How the pandemic is changing medicine

By Jonathan D. Moreno & Stephen N. Xenakis

thehill.com – “There have been many plagues in the world as there have been wars,” Albert Camus wrote, “yet plagues and wars always find people equally unprepared.” Both plagues and wars, horrific and tragic, strike the soul of a society, its core beliefs and practices. The battle against the novel coronavirus is already changing the way medicine is practiced.

To view the original article in its entirety, click here.

Analysis reveals how people around the world respond to depression treatment

By Shraddha Chakradhar

statnews.com – A new review of mental health surveys from 16 countries around the world offers a glimpse into how those with depression respond to treatment. More than 80,000 who took the WHO’s World Mental Health survey between 2002-2016 were included in the analysis.

To view the original article in its entirety, click here.

UN expects global human development to fall for the first time on record this year

By Sam Meredith

cnbc.com – The United Nations Development Programme (UNDP) has warned the coronavirus pandemic is “unleashing a human development crisis,” with declines in fundamental areas of living standards expected to be felt across most countries, rich and poor, in every region.

The report, published on Wednesday, estimates that global human development — which is a combined measure of the world’s education, health and living standards — is on pace to decline for the first time since the concept was developed in 1990.

To view the original article in its entirety, click here.

PRESS RELEASE: Echosens and NASHNET Recognize International NASH Day, June 12, 2020: Collaboration, Best Practices and Early Detection of Fatty Liver Disease

PARIS and Waltham, MA – June 8, 2020 – Echosens, a high-technology company offering the FibroScan family of products, joins healthcare leaders worldwide in recognition of International NASH Day, June 12, 2020, a series of virtual events via a global social media campaign, to increase awarenessabout non-alcoholic steatohepatitis (NASH) among the general public, at-risk patients, the medical community, public health authorities and the media. The more severe form of nonalcoholic fatty liver disease (NAFLD), NASH is an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity.

“While the COVID-19 pandemic limits locally organized events for this important day, we support advocates who are raising awareness and promoting early intervention to treat fatty liver disease and NASH, which affects more than 115 million people worldwide,” says Dominique Legros, Echosens Group CEO, based at the corporate headquarters and offices in Paris, France. “While the threat of contracting coronavirus weighs heavily, increasingly people are living with advancing liver disease. In these stressful times, liver health matters.”

Estimates show that 357 million people will have NASH globally by 2030. Because NASH symptoms are not obvious in the early stage of the disease, it is often underreported and diagnosed at an advanced critical stage.

Jon Gingrich, CEO, Echosens North America, explains, “The need for point-of-care examinations, monitoring and ongoing assessment of liver fat and stiffness as provided by FibroScan and the FAST Score are critical to helping identify individuals with NASH at risk of progression to cirrhosis.

FibroScan is the most widely studied tool in the world for non-invasive quantitative liver assessment in point of care with over 6,000+ FibroScan system placed worldwide and 1,200 FibroScan systems placed in healthcare settings across the United States – including physician offices, diagnostic centers and hospitals. It is expected that FibroScan examinations will be performed as a routine part of patient management.”

Furthermore, NAFLD and NASH are major risk factors for concurrent conditions: more than 70% of patients are obese, up to 75% have Type 2 diabetes, and 20-80% have hyperlipidemia. Unchecked, NASH may lead to cirrhosis, liver cancer and liver transplant.

Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, in collaboration with NASHNET, a global Centers  of  Excellence Network represented by leading healthcare systems in collaboration with The Kinetix Group, states, “International NASH Day calls for unity, collaboration, innovation, best practice sharing and the development of real-world evidence to create standardization and systematization of care models that address major NAFLD/NASH gaps to battle this growing epidemic.”

About Echosens
 Pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the first non-invasive solution to assess and monitor patients with chronic liver disease. FibroScan® is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 2,500+ peer reviewed publications and 40+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. www.echosens.com

About NASHNET
 NASHNET, a Kinetix Group-led network founded in 2017, aims to improve non-alcoholic fatty liver disease (NAFLD) care delivery by promoting collaboration, innovation, best practice sharing, and the development of real-world evidence across leading delivery systems. NASHNET aims to create standardization and systematization of care models that address major NAFLD/NASH gaps including patient identification and stratification, referrals and intervention methodologies, care coordination processes, and patient and provider education from primary care through hepatology.

Media:

Brittany Tedesco
CPR Communications

btedesco@cpronline.com

201.641.1911 x 14

Claire Mario

claire.mario@echosens.com

+33(0)1-44-82-78-50

To view the official press release in its entirety, click here.

Leave a Reply

Top